Stay Updated with the Latest Lazard Next Gen Technologies ETF TEKY News in Real Time
Find TEKY news now at Meyka AI. Stay informed with the latest Lazard Next Gen Technologies ETF stocks updates, including price news, market analysis, and expert insights.
Massive Storm System Drenches Australia; Flooding Hits Victoria, NSW on August 24
A major low-pressure system is bringing heavy rain and storms across southeast Australia through Tuesday. Victoria and NSW face flooding risks as catchments remain saturated from recent rainfall.
Cardano Jumps 13.8% to $0.2266 as RSI Hits Overbought 69.5
ADAUSD surged 13.8% to $0.2266 in 24 hours with RSI at 69.5 and volume 63% above average, signaling strong short-term momentum.
Sui USD Surges 15.9% to $0.8508 as RSI Hits 66.9 on Strong Momentum
Sui USD jumped 15.9% to $0.8508 in 24 hours with volume 2.3x average. RSI at 66.9 and ADX at 29.95 signal strong upward momentum.
Bitcoin Cash Surges 23% to $274.84 as Japan Licensing Fuels Institutional Demand
Bitcoin Cash jumped 23.3% to $274.84 on August 23, 2026, after Japan approved its first new crypto trading license in four years, enabling regulated access for professional investors.
Bitcoin Jumps 6.4% to $77,699 as Volatility-Adjusted Rally Signals Regime Shift
Bitcoin surges 6.4% to $77,699 in a volatility-adjusted move analysts compare to the fifth-largest since 2018, signaling a potential bull market inflection.
Lido Staked ETH USD Rallies 5.9% to $2,462 as Momentum Indicators Flash Overbought
STETHUSD jumped 5.9% to $2,462.17 in 24 hours with RSI at 83.88 and price above Bollinger upper band, signaling extreme overbought conditions.
Ethereum Surges 5.9% to $2,464.69 as RSI Hits Extreme Overbought 84.7
Ethereum USD jumped 5.9% to $2,464.69 in 24 hours with RSI at 84.7, signaling extreme overbought conditions and a potential pullback.
Solana Climbs 8.5% to $95.08 as RSI Hits Extreme Overbought 78.7
Solana USD surged 8.5% to $95.08 in 24 hours with RSI at 78.7, signaling overbought conditions and potential pullback risk.
Moderna and Merck’s Melanoma Vaccine Jumps Stocks on Phase 3 Win
Moderna and Merck’s personalized mRNA cancer vaccine succeeded in Phase 3 melanoma trials, reducing disease recurrence. MRNA jumped 8.9% and MRK rose 2.4% on the announcement.